The FDA approved the oral SERD giredestrant with everolimus for ESR1-mutated, ER-positive, HER2-negative advanced breast cancer based on phase 3 evERA data.
The approval of pertuzumab-qcay (Pebrilzo) covers metastatic and early-stage HER2-positive breast cancer, but a patent settlement with Genentech delays its earliest US launch until the third quarter of 2028.